Amer Sami
Impact in
- Cancer Research top 5%
- Breast Cancer Treatment Studies
- Oncology top 10%
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
Papers in
-
- Immunotherapy and Immune Responses 8
- Oncology 6
- HER2/EGFR in Cancer Research 3
- PARP inhibition in cancer therapy 1
- Lung Cancer Research Studies 1
- Co-authors
- Shahid Ahmed (13 shared papers)Jim Xiang (5 shared papers)Kamal Haider (6 shared papers)Sunil Kumar Yadav (3 shared papers)Riaz Alvi (2 shared papers)Ali Abdel Halim El-Gayed (6 shared papers)J Xiang (4 shared papers)David R. Popkin (2 shared papers)
- Journals
- Cancer Gene Therapy (3 papers)Annals of Oncology (2 papers)Cancers (2 papers)Gene Therapy (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- CanadaChinaUnited States
In The Last Decade
Amer Sami
20 papers receiving 1.2k citations
Amer Sami's Hit Papers
Peers
Comparison fields: 5 of 72
- Cancer Research 282
- Oncology 353
- Immunology 125
- Emergency Medicine 36
- Emergency Medical Services 27
Countries citing papers authored by Amer Sami
This map shows the geographic impact of Amer Sami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer Sami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer Sami more than expected).
Fields of papers citing papers by Amer Sami
This network shows the impact of papers produced by Amer Sami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer Sami. The network helps show where Amer Sami may publish in the future.
Co-authors
The 25 scholars most cited alongside Amer Sami, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 2 | 2012 | 181 | |
| 3 | 2015 | 154 | |
| 4 | 2014 | 150 | |
| 5 | 2006 | 106 | |
| 6 | 2013 | 44 | |
| 7 | 2021 | 43 | |
| 8 | 2010 | 41 | |
| 9 | 2006 | 33 | |
| 10 | 2018 | 27 | |
| 11 | 2021 | 25 | |
| 12 | 2008 | 23 | |
| 13 | 2013 | 16 | |
| 14 | 2006 | 12 | |
| 15 | 2011 | 11 | |
| 16 | 2022 | 11 | |
| 17 | 2021 | 7 | |
| 18 | 2015 | 5 | |
| 19 | 2008 | 2 | |
| 20 | 2023 | 1 |
About Amer Sami
Amer Sami is a scholar working on Immunology, Oncology, Pulmonary and Respiratory Medicine, Emergency Medical Services and Cancer Research, having authored 20 papers that have together received 1.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (8 papers), HER2/EGFR in Cancer Research (3 papers), Advanced Breast Cancer Therapies (2 papers), PARP inhibition in cancer therapy (1 paper), Male Breast Health Studies (1 paper), Central Venous Catheters and Hemodialysis (1 paper), Neuroendocrine Tumor Research Advances (1 paper) and Lung Cancer Research Studies (1 paper). The work is most often cited by research in Cancer Research (282 citations), Oncology (353 citations), Immunology (125 citations), Emergency Medicine (36 citations) and Emergency Medical Services (27 citations). Amer Sami has collaborated with scholars based in Canada, China and United States. Frequent co-authors include Shahid Ahmed, Jim Xiang, Kamal Haider, Sunil Kumar Yadav, Riaz Alvi, Ali Abdel Halim El-Gayed, J Xiang, David R. Popkin, Rabia K. Shahid and Imran Ahmad. Their work appears in journals such as Cancer Gene Therapy, Annals of Oncology, Cancers, Gene Therapy and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.